In a March 25 update, HHS said sotrovimab shipments to HHS Region 1 (Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island and Vermont) and Region 2 (New Jersey, New York, Puerto Rico and the Virgin Islands) will be paused immediately. HHS cited alternative treatments — including bebtelovimab, a monoclonal antibody, and COVID-19 antivirals Paxlovid and molnupiravir — that current data has shown to be effective against BA.2.
The FDA said new data “shows that the authorized dose of sotrovimab is unlikely to be effective against the BA.2 subvariant.”
“We will continue to monitor BA.2 in all U.S. regions and may revise the authorization further to ensure that patients with COVID-19 have effective treatments available. Healthcare providers should also monitor the frequency of BA.2 in their region as they choose appropriate treatment options for patients.”
The CDC estimates the omicron subvariant accounted for about 35 percent of U.S. cases for the week ending March 25.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
